Skip to main content
OpenTrials
Completed

NCT Number: NCT02011204

Study of Electrical Impedance Myography (EIM) in ALS

This trial is studying Electrical Impedance Myography (EIM) for measuring muscle health. The trial is studying people with Amyotrophic Lateral Sclerosis (ALS), other neuromuscular diseases, and healthy volunteers to see if the EIM device can measure disease in muscle tissue.

Completed

Looking for future studies?

Notify Me

Key information

About this study

This is a multicenter, 9-month study evaluating the effectiveness of electrical impedance myography (EIM) as a diagnostic and disease-tracking tool. In addition, the following will be studied:

  • Determine EIM device's ability to discriminate between ALS and "look-alike" non-fatal, motor-predominant syndromes;
  • Track EIM progression over time and determine the best summary EIM measure that could serve as an endpoint in future clinical trials and individual patient care; and,
  • Determine whether EIM progression is predictive of a combined outcome of survival and progression as measured by ALS Functional Rating Scale, Revised (ALSFRS-R), Hand-held Dynamometry (HHD) and Vital Capacity (VC) measures.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Early ALS Inclusion Criteria:

  • Sporadic or familial ALS (as defined by revised El Escorial criteria)
  • Onset of weakness or spasticity due to ALS ≤ 36 months prior to the Screening/Baseline Visit.
  • Slow vital capacity (SVC) ≥60% of predicted for gender, height, and age

Early ALS Exclusion Criteria:

  • The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, or a history of active substance abuse within the prior year.

ALS Disease Mimics Inclusion Criteria:

  • Diagnosis of one of the following:

a. Pure Lower Motor Neuron Disease (LMND) mimics: i. Multi-focal motor neuropathy ii. Autoimmune motor neuropathy iii. Cervical or lumbosacral radiculopathies with weakness involving more than one extremity or more than a single myotome if restricted to one extremity.

iv. Multiple peripheral mononeuropathies with clinical weakness v. Charcot-Marie-Tooth Disease vi. Any condition that produces generalized or localized weakness without concomitant sensory symptoms, including myasthenia gravis or myopathy, that the evaluating physician deems mimics ALS.

b. Pure Upper Motor Neuron Disease (UMND) mimics: i. Cervical myelopathy ii. Multiple sclerosis iii. Hereditary spastic paraparesis

ALS Disease Mimics Exclusion Criteria:

  • Diagnosis of possible, probable, probable-laboratory supported, or definite ALS
  • Presence of positive family history of ALS.
  • The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, or a history of active substance abuse within the prior year.

Healthy Volunteer Inclusion Criteria:

  • Absence of a known neurological disorder.

Healthy Volunteer Exclusion Criteria:

  • History of ALS, myopathy, neuropathy, ALS mimic disorder or other neurodegenerative disease.
  • Presence of positive family history of ALS.
  • The presence of unstable psychiatric disease, cognitive impairment, or dementia that would impair ability of the subject to provide informed consent, or a history of active substance abuse within the prior year.

*Please note that this is not a complete listing on all eligibility criteria.*

Treatment and study plan

electrical impedance myography (EIM)

Device

In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.

EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time.

Other names: EIM1102 device

Primary outcomes

  1. Discrimination between Groups

    Time frame: Duration of the Study (9 months for Group A, one visit for Groups B and C)

    Determine EIM device's ability to discriminate between ALS and "look-alike" non-fatal, motor-predominant syndromes

Secondary outcomes

  1. Tracking Progression

    Time frame: Duration of Study, (9 months for Group A, one visit for Groups B and C)

    Track EIM progression over time and determine the best summary EIM measure that could serve as an endpoint in future clinical trials and individual patient care

  2. Correlation with Outcome Measures

    Time frame: Duration of Study (9 months for Group A, one visit for Groups B and C)

    Determine whether EIM progression is predictive of a combined outcome of survival and progression as measured by ALSFRS-R, HHD and VC.

Sponsors and collaborators

Lead sponsor

Skulpt, Inc.

Industry

Registry information

Official study title

Noninvasive Assessment of Neuromuscular Disease Using Electrical Impedance

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Dec 13, 2013
Registry last updated
May 11, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.